AS/Spondyloarthritis
Eric Dein ericdeinmd
2 years 9 months ago
L14 #ACR22 Bimekizumab BE MOBILE 1 and 2
Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nrAxSpA, 45% AS) to W52 (61%, 58%). Efficacy in TNF-naive & TNF-failure.
AEs: Nasopharyngitis (12% nrAxSpA, 9% AS), URI (9, 6%), candidiasis (7, 6%), COVID (7, 2%)
@RheumNow https://t.co/G31PrfqtVu
Eric Dein ericdeinmd
2 years 9 months ago
L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS
P3b: SEC 150 mg v SEC 300 v SDZ-ADL
Wk 104: no radiographic progression in 66%, 67%, 66% - no statistical significance
Hard to assess as overall, low rate of progression
@RheumNow
Catherine Sims, MD DrCassySims
2 years 9 months ago
Does tofacitinib work better in patients with PsA and AS who smoke?
Abstract #1036 #ACR22 @RheumNow
🚬519 ever smokers
🚭767 never smokers
💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO
✋Overall, efficacy was generally comparable in ever v. never 🚬
Catherine Sims, MD DrCassySims
2 years 9 months ago
Abstract #PP25
Patient mantra on life with SpA: “not to over-exert the body on your good days and always strive to be active on your bad days”
Patient recommended exercise:
🏓table tennis
🏊♂️swimming
🧘yoga
🤸tai chi
#ACR22 @RheumNow
Dr. Antoni Chan synovialjoints
2 years 9 months ago
Bimekizumab (BKZ) in AxSpA to Wk52
◦ sustained efficacy
◦ suppression of inflammation
◦ improvements in function and quality of life
◦ no new safety signals were observed
◦ consistent with the safety profileWk24 data
Baraliakos #L14 https://t.co/gk23g4vqQl #ACR22 @RheumNow
Catherine Sims, MD DrCassySims
2 years 9 months ago
Mortality in patients with SpA
Abstract #0569 #ACR22 @RheumNow
✏️systematic review/meta-analysis of 19 studies
✋No increased mortality in patients with PsA compared to gen. pop.
🦠Infection, 🫀CV, and 🫁 pulm. specific mortality sig. higher in PsA patients
Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.
Richard Conway RichardPAConway
2 years 9 months ago
Karmacharya @rheum_cat et al. Comorbidity clusters in AS. Depression cluster associated higher disease activity and worse function over time. @RheumNow #ACR22 Abstr#1609 https://t.co/lFVoyhy5UQ https://t.co/26EjzXULGr
Dr. Antoni Chan synovialjoints
2 years 9 months ago
Spinal lesions on MRI in axSpA is ~3% in patients with negative imaging in SIJ on MRI or X-ray. Agreement in >5/9 central readers. Frequency of spinal vertebral corner BME lesions was significantly higher these cases. Maksymovych Abs#2257 https://t.co/56yxGxBgLp #ACR22 @RheumNow https://t.co/CkJ9o2dJuT
Akhil Sood MD AkhilSoodMD
2 years 9 months ago
Does lifestyle impact Tx. response?
#Abstr 1510 looked at effect of lifestyle on TNFi response in #axSpA
- The study found higher BMI (obese, overweight) and smoking were less likely to respond to TNFi
- Important to discuss lifestyle when starting tx.
@RheumNow #ACR22 https://t.co/z98DFMLxu3
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for #ACRbest abstracts today:
Poster Hall